메뉴 건너뛰기




Volumn 30, Issue 5, 2003, Pages 698-708

Differentiating Agents and the Treatment of Prostate Cancer: Vitamin D 3 and Peroxisome Proliferator-Activated Receptor Gamma Ligands

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN RECEPTOR; CALCIFEDIOL; CALCITRIOL; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; DEXAMETHASONE; DOCETAXEL; KETOCONAZOLE; MITOXANTRONE; OXYGENASE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE; VITAMIN D RECEPTOR; ZOLEDRONIC ACID;

EID: 0142126160     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00352-X     Document Type: Article
Times cited : (16)

References (71)
  • 2
    • 0032497522 scopus 로고    scopus 로고
    • Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
    • Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
    • (1998) N Engl J Med , vol.339 , pp. 1036-1042
    • Eisenberger, M.A.1    Blumenstein, B.A.2    Crawford, E.D.3
  • 3
    • 0032784113 scopus 로고    scopus 로고
    • Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
    • Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 2506-2513
    • Kantoff, P.W.1    Halabi, S.2    Conaway, M.3
  • 4
    • 8944220720 scopus 로고    scopus 로고
    • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
    • Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 1756-1764
    • Tannock, I.F.1    Osoba, D.2    Stockler, M.R.3
  • 5
    • 0025882306 scopus 로고
    • Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
    • Warrell RP Jr, Frankel SR, Miller WH Jr, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385-1393, 1991
    • (1991) N Engl J Med , vol.324 , pp. 1385-1393
    • Warrell R.P., Jr.1    Frankel, S.R.2    Miller W.H., Jr.3
  • 6
    • 0025201879 scopus 로고
    • All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results
    • Castaigne S, Chomienne C, Daniel MT, et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 76:1704-1709, 1990
    • (1990) Blood , vol.76 , pp. 1704-1709
    • Castaigne, S.1    Chomienne, C.2    Daniel, M.T.3
  • 7
    • 0026040363 scopus 로고
    • A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
    • Chen ZX, Xue YQ, Zhang R, et al: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413-1419, 1991
    • (1991) Blood , vol.78 , pp. 1413-1419
    • Chen, Z.X.1    Xue, Y.Q.2    Zhang, R.3
  • 9
    • 0035342671 scopus 로고    scopus 로고
    • The role of vitamin D in prostate cancer
    • Zhao XY, Feldman D: The role of vitamin D in prostate cancer. Steroids 66:293-300, 2001
    • (2001) Steroids , vol.66 , pp. 293-300
    • Zhao, X.Y.1    Feldman, D.2
  • 10
    • 0025187312 scopus 로고
    • Is vitamin D deficiency a risk factor for prostate cancer?
    • Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307-1311, 1990
    • (1990) Anticancer Res , vol.10 , pp. 1307-1311
    • Schwartz, G.G.1    Hulka, B.S.2
  • 11
    • 0027664955 scopus 로고
    • Vitamin D and prostate cancer: A prediagnostic study with stored sera
    • Corder EH, Guess HA, Hulka BS, et al: Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-472, 1993
    • (1993) Cancer Epidemiol Biomarkers Prev , vol.2 , pp. 467-472
    • Corder, E.H.1    Guess, H.A.2    Hulka, B.S.3
  • 12
    • 0029160549 scopus 로고
    • Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men
    • Corder EH, Friedman GD, Vogelman JH, et al: Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 4:655-659, 1995
    • (1995) Cancer Epidemiol Biomarkers Prev , vol.4 , pp. 655-659
    • Corder, E.H.1    Friedman, G.D.2    Vogelman, J.H.3
  • 13
    • 0033785622 scopus 로고    scopus 로고
    • Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels
    • Ahonen MH, Tenkanen L, Teppo L, et al: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11:847-852, 2000
    • (2000) Cancer Causes Control , vol.11 , pp. 847-852
    • Ahonen, M.H.1    Tenkanen, L.2    Teppo, L.3
  • 14
    • 0029014444 scopus 로고
    • Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
    • Braun MM, Helzlsouer KJ, Hollis BW, et al: Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6:235-239, 1995
    • (1995) Cancer Causes Control , vol.6 , pp. 235-239
    • Braun, M.M.1    Helzlsouer, K.J.2    Hollis, B.W.3
  • 15
    • 0031719143 scopus 로고    scopus 로고
    • Serum vitamin D metabolite levels and the subsequent development of prostate cancer
    • Nomura AM, Stemmermann GN, Lee J, et al: Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9:425-432, 1998
    • (1998) Cancer Causes Control , vol.9 , pp. 425-432
    • Nomura, A.M.1    Stemmermann, G.N.2    Lee, J.3
  • 16
    • 33846319260 scopus 로고    scopus 로고
    • Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
    • Gann PH, Ma J, Hennekens CH, et al: Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5:121-126, 1996
    • (1996) Cancer Epidemiol Biomarkers Prev , vol.5 , pp. 121-126
    • Gann, P.H.1    Ma, J.2    Hennekens, C.H.3
  • 18
    • 0029914170 scopus 로고    scopus 로고
    • The role of vitamin D in normal prostate growth and differentiation
    • Konety BR, Schwartz GG, Acierno JS Jr, et al: The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7:1563-1570, 1996
    • (1996) Cell Growth Differ , vol.7 , pp. 1563-1570
    • Konety, B.R.1    Schwartz, G.G.2    Acierno J.S., Jr.3
  • 24
    • 0028168202 scopus 로고
    • Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
    • Schwartz GG, Oeler TA, Uskokovic MR, et al: Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1081, 1994
    • (1994) Anticancer Res , vol.14 , pp. 1077-1081
    • Schwartz, G.G.1    Oeler, T.A.2    Uskokovic, M.R.3
  • 26
    • 0031463720 scopus 로고    scopus 로고
    • Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
    • Getzenberg RH, Light BW, Lapco PE, et al: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50:999-1006, 1997
    • (1997) Urology , vol.50 , pp. 999-1006
    • Getzenberg, R.H.1    Light, B.W.2    Lapco, P.E.3
  • 27
    • 0032963132 scopus 로고    scopus 로고
    • Inhibition of prostate cancer metastasis in vivo: A comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089
    • Lokeshwar BL, Schwartz GG, Selzer MG, et al: Inhibition of prostate cancer metastasis in vivo: A comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8:241-248, 1999
    • (1999) Cancer Epidemiol Biomarkers Prev , vol.8 , pp. 241-248
    • Lokeshwar, B.L.1    Schwartz, G.G.2    Selzer, M.G.3
  • 29
    • 0036379695 scopus 로고    scopus 로고
    • 3 and two synthetic analogues in three in vivo models of prostate cancer
    • 3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 90:607-616, 2002
    • (2002) BJU Int , vol.90 , pp. 607-616
    • Oades, G.M.1    Dredge, K.2    Kirby, R.S.3
  • 30
    • 0032937372 scopus 로고    scopus 로고
    • 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells
    • 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205-1212, 1999
    • (1999) Endocrinology , vol.140 , pp. 1205-1212
    • Zhao, X.Y.1    Ly, L.H.2    Peehl, D.M.3
  • 31
    • 85047683799 scopus 로고    scopus 로고
    • 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms
    • 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141:2548-2556, 2000
    • (2000) Endocrinology , vol.141 , pp. 2548-2556
    • Zhao, X.Y.1    Peehl, D.M.2    Navone, N.M.3
  • 32
    • 0034463114 scopus 로고    scopus 로고
    • Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2
    • Blutt SE, McDonnell TJ, Polek TC, et al: Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17, 2000
    • (2000) Endocrinology , vol.141 , pp. 10-17
    • Blutt, S.E.1    McDonnell, T.J.2    Polek, T.C.3
  • 33
    • 0030910440 scopus 로고    scopus 로고
    • 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
    • 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138: 1491-1497, 1997
    • (1997) Endocrinology , vol.138 , pp. 1491-1497
    • Blutt, S.E.1    Allegretto, E.A.2    Pike, J.W.3
  • 34
    • 85047680777 scopus 로고    scopus 로고
    • 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
    • 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998
    • (1998) Endocrinology , vol.139 , pp. 1197-1207
    • Zhuang, S.H.1    Burnstein, K.L.2
  • 38
    • 0030809595 scopus 로고    scopus 로고
    • 1 Alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
    • Schwartz GG, Wang MH, Zang M, et al: 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727-732, 1997
    • (1997) Cancer Epidemiol Biomarkers Prev , vol.6 , pp. 727-732
    • Schwartz, G.G.1    Wang, M.H.2    Zang, M.3
  • 39
    • 0034691008 scopus 로고    scopus 로고
    • 3 decreases human prostate cancer cell adhesion and migration
    • 3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164:133-143, 2000
    • (2000) Mol Cell Endocrinol , vol.164 , pp. 133-143
    • Sung, V.1    Feldman, D.2
  • 40
    • 85047685002 scopus 로고    scopus 로고
    • Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells
    • Bernardi RJ, Johnson CS, Modzelewski RA, et al: Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508-2514, 2002
    • (2002) Endocrinology , vol.143 , pp. 2508-2514
    • Bernardi, R.J.1    Johnson, C.S.2    Modzelewski, R.A.3
  • 41
    • 8844273350 scopus 로고    scopus 로고
    • Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression
    • Krishnan AV, Peehl DM, Feldman D: Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88:363-371, 2003
    • (2003) J Cell Biochem , vol.88 , pp. 363-371
    • Krishnan, A.V.1    Peehl, D.M.2    Feldman, D.3
  • 42
    • 0032978243 scopus 로고    scopus 로고
    • A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy
    • Smith DC, Johnson CS, Freeman CC, et al: A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5:1339-1345, 1999
    • (1999) Clin Cancer Res , vol.5 , pp. 1339-1345
    • Smith, D.C.1    Johnson, C.S.2    Freeman, C.C.3
  • 43
    • 0036716825 scopus 로고    scopus 로고
    • Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer
    • Liu G, Oettel K, Ripple G, et al: Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 8:2820-2827, 2002
    • (2002) Clin Cancer Res , vol.8 , pp. 2820-2827
    • Liu, G.1    Oettel, K.2    Ripple, G.3
  • 44
    • 0035875881 scopus 로고    scopus 로고
    • A Phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation
    • Beer TM, Munar M, Henner WD: A Phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation. Cancer 91:2431-2439, 2001
    • (2001) Cancer , vol.91 , pp. 2431-2439
    • Beer, T.M.1    Munar, M.2    Henner, W.D.3
  • 45
    • 0001013226 scopus 로고
    • Phase II trial of oral 1,25 dihydroxyvitamin D (calcitriol) in hormone-refractory prostate cancer
    • Osborn JL, Schwartz GG, Smith DC, et al: Phase II trial of oral 1,25 dihydroxyvitamin D (calcitriol) in hormone-refractory prostate cancer. Urol Oncol 1:195-198, 1995
    • (1995) Urol Oncol , vol.1 , pp. 195-198
    • Osborn, J.L.1    Schwartz, G.G.2    Smith, D.C.3
  • 47
    • 0037372282 scopus 로고    scopus 로고
    • High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma
    • Beer TM, Lemmon D, Lowe BA, et al: High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97:1217-1224, 2003
    • (2003) Cancer , vol.97 , pp. 1217-1224
    • Beer, T.M.1    Lemmon, D.2    Lowe, B.A.3
  • 48
    • 0037208558 scopus 로고    scopus 로고
    • Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer
    • Beer TM, Eilers KM, Garzotto M, et al: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123-128, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 123-128
    • Beer, T.M.1    Eilers, K.M.2    Garzotto, M.3
  • 49
    • 0036075032 scopus 로고    scopus 로고
    • Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model
    • Ahmed S, Johnson CS, Rueger RM, et al: Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 168:756-761, 2002
    • (2002) J Urol , vol.168 , pp. 756-761
    • Ahmed, S.1    Johnson, C.S.2    Rueger, R.M.3
  • 50
    • 0034908713 scopus 로고    scopus 로고
    • Rationale for combination ketoconazole/vitamin D treatment of prostate cancer
    • Peehl DM, Seto E, Feldman D: Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. Urology 58:123-126, 2001
    • (2001) Urology , vol.58 , pp. 123-126
    • Peehl, D.M.1    Seto, E.2    Feldman, D.3
  • 51
    • 0003303383 scopus 로고    scopus 로고
    • 3) + dexamethasone in androgen independent prostate cancer (AIPC)
    • abstr
    • 3) + dexamethasone in androgen independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 19:1327, 2000 (abstr)
    • (2000) Proc Am Soc Clin Oncol , vol.19 , pp. 1327
    • Trump, D.1    Serafine, S.2    Brufsky, A.3
  • 53
    • 0034943192 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells
    • Nwankwo JO, Robbins ME: Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 64:241-245, 2001
    • (2001) Prostaglandins Leukot Essent Fatty Acids , vol.64 , pp. 241-245
    • Nwankwo, J.O.1    Robbins, M.E.2
  • 54
    • 0036286540 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor gamma (PPARgamma) as a novel target for prostate cancer
    • Smith MR, Kantoff PW: Peroxisome proliferator-activated receptor gamma (PPARgamma) as a novel target for prostate cancer. Invest New Drugs 20:195-200, 2002
    • (2002) Invest New Drugs , vol.20 , pp. 195-200
    • Smith, M.R.1    Kantoff, P.W.2
  • 55
    • 0033616795 scopus 로고    scopus 로고
    • Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma
    • Demetri GD, Fletcher CD, Mueller E, et al: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96:3951-3956, 1999
    • (1999) Proc Natl Acad Sci USA , vol.96 , pp. 3951-3956
    • Demetri, G.D.1    Fletcher, C.D.2    Mueller, E.3
  • 56
    • 12644265334 scopus 로고    scopus 로고
    • Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
    • Tontonoz P, Singer S, Forman BM, et al: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94:237-241, 1997
    • (1997) Proc Natl Acad Sci USA , vol.94 , pp. 237-241
    • Tontonoz, P.1    Singer, S.2    Forman, B.M.3
  • 57
    • 0032586875 scopus 로고    scopus 로고
    • Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells
    • Takahashi N, Okumura T, Motomura W, et al: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455:135-139, 1999
    • (1999) FEBS Lett , vol.455 , pp. 135-139
    • Takahashi, N.1    Okumura, T.2    Motomura, W.3
  • 58
    • 0033741281 scopus 로고    scopus 로고
    • Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists
    • Sato H, Ishihara S, Kawashima K, et al: Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 83:1394-1400, 2000
    • (2000) Br J Cancer , vol.83 , pp. 1394-1400
    • Sato, H.1    Ishihara, S.2    Kawashima, K.3
  • 59
    • 0035458324 scopus 로고    scopus 로고
    • PPARgamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis cell cycle arrest and reduction of ornithine decarboxylase activity
    • Takashima T, Fujiwara Y, Higuchi K, et al: PPARgamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 19:465-471, 2001
    • (2001) Int J Oncol , vol.19 , pp. 465-471
    • Takashima, T.1    Fujiwara, Y.2    Higuchi, K.3
  • 60
    • 0031671246 scopus 로고    scopus 로고
    • Differentiation and reversal of malignant changes in colon cancer through PPARgamma
    • Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052, 1998
    • (1998) Nat Med , vol.4 , pp. 1046-1052
    • Sarraf, P.1    Mueller, E.2    Jones, D.3
  • 61
    • 0031993322 scopus 로고    scopus 로고
    • Terminal differentiation of human breast cancer through PPAR gamma
    • Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1:465-470, 1998
    • (1998) Mol Cell , vol.1 , pp. 465-470
    • Mueller, E.1    Sarraf, P.2    Tontonoz, P.3
  • 62
    • 0035964872 scopus 로고    scopus 로고
    • Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists
    • Inoue K, Kawahito Y, Tsubouchi Y, et al: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287:727-732, 2001
    • (2001) Biochem Biophys Res Commun , vol.287 , pp. 727-732
    • Inoue, K.1    Kawahito, Y.2    Tsubouchi, Y.3
  • 63
    • 0036754728 scopus 로고    scopus 로고
    • Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists
    • Hase T, Yoshimura R, Mitsuhashi M, et al: Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 60:542-547, 2002
    • (2002) Urology , vol.60 , pp. 542-547
    • Hase, T.1    Yoshimura, R.2    Mitsuhashi, M.3
  • 64
    • 0033152206 scopus 로고    scopus 로고
    • Loss-of-function mutations in PPAR gamma associated with human colon cancer
    • Sarraf P, Mueller E, Smith WM, et al: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3:799-804, 1999
    • (1999) Mol Cell , vol.3 , pp. 799-804
    • Sarraf, P.1    Mueller, E.2    Smith, W.M.3
  • 65
    • 0036730017 scopus 로고    scopus 로고
    • A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
    • Kulke MH, Demetri GD, Sharpless NE, et al: A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8:395-399, 2002
    • (2002) Cancer J , vol.8 , pp. 395-399
    • Kulke, M.H.1    Demetri, G.D.2    Sharpless, N.E.3
  • 66
    • 0036570532 scopus 로고    scopus 로고
    • Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer
    • Segawa Y, Yoshimura R, Hase T, et al: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51:108-116, 2002
    • (2002) Prostate , vol.51 , pp. 108-116
    • Segawa, Y.1    Yoshimura, R.2    Hase, T.3
  • 67
    • 0343855442 scopus 로고    scopus 로고
    • Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer
    • Mueller E, Smith M, Sarraf P, et al: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97:10990-10995, 2000
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 10990-10995
    • Mueller, E.1    Smith, M.2    Sarraf, P.3
  • 68
    • 0032145363 scopus 로고    scopus 로고
    • Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
    • Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352, 1998
    • (1998) Cancer Res , vol.58 , pp. 3344-3352
    • Kubota, T.1    Koshizuka, K.2    Williamson, E.A.3
  • 69
    • 0034306976 scopus 로고    scopus 로고
    • Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer
    • Hisatake JI, Ikezoe T, Carey M, et al: Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60:5494-5498, 2000
    • (2000) Cancer Res , vol.60 , pp. 5494-5498
    • Hisatake, J.I.1    Ikezoe, T.2    Carey, M.3
  • 71
    • 0142061276 scopus 로고    scopus 로고
    • Identification of PPAR gamma specific target genes in prostate cancer cells
    • abstr
    • Mueller E, Febbo P, Sarraf P, et al: Identification of PPAR gamma specific target genes in prostate cancer cells. Proc Am Assoc Cancer Res 44:605, 2003 (abstr)
    • (2003) Proc Am Assoc Cancer Res , vol.44 , pp. 605
    • Mueller, E.1    Febbo, P.2    Sarraf, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.